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he wnt pathway regulates the steady state level of
 
 
 
-catenin, a transcriptional coactivator for the Tcf3/
Lef1 family of DNA binding proteins. We demonstrate
 
that Tcf3 can inhibit 
 
 
 
-catenin turnover via its competition
with axin and adenomatous polyposis for 
 
 
 
-catenin binding.
A mutant of 
 
 
 
-catenin that cannot bind Tcf3 is degraded faster
 
than the wild-type protein in 
 
Xenopus
 
 embryos and extracts.
 
A fragment of 
 
 
 
-catenin and a peptide encoding the NH
 
2
 
terminus of Tcf4 that block the interaction between 
 
 
 
-catenin
and Tcf3 stimulate 
 
 
 
-catenin degradation, indicating this
interaction normally plays an important role in regulating
 
 
 
-catenin turnover. Tcf3 is a substrate for both glycogen
T
 
synthase kinase (GSK) 3 and casein kinase (CK) 1
 
 
 
, and
 
phosphorylation of Tcf3 by CKI
 
 
 
 stimulates its binding to
 
 
 
-catenin, an effect reversed by GSK3. Tcf3 synergizes with
CK1
 
 
 
 to inhibit 
 
 
 
-catenin degradation, whereas CKI-7, an
 
inhibitor of CK1
 
 
 
, reduces the inhibitory effect of Tcf3.
Finally, we provide evidence that CK1
 
 
 
 stimulates the
binding of dishevelled (dsh) to GSk3 binding protein (GBP)
in extracts. Along with evidence that a signiﬁcant amount
of Tcf protein is nonnuclear, these ﬁndings suggest that
CK1
 
 
 
 can modulate wnt signaling in vivo by regulating
both the 
 
 
 
-catenin-Tcf3 and the GBP-dsh interfaces.
 
Introduction
 
Wnt signaling plays an important role in the development of
all metazoan embryos and in the genesis of several human
malignancies (for review see Morin, 1999). In the presence
of a wnt signal, the transcriptional activation of target genes
is initiated as a result of increased steady state levels of the
transcriptional coactivator 
 
 
 
-catenin. In the absence of wnt
activity, soluble 
 
 
 
-catenin is an unstable protein with an esti-
mated half-life of 1–1.5 h in 
 
Xenopus
 
 embryos. Degradation
of 
 
 
 
-catenin occurs through the coordinated assembly of a
complex that contains 
 
 
 
-catenin, axin, glycogen synthase
kinase (GSK)* 3, and the adenomatous polyposis coli (APC)
protein. Within this complex, 
 
 
 
-catenin is brought in the
proximity of and is phosphorylated by GSK3 (Kishida et al.,
1998). Phosphorylated 
 
 
 
-catenin is subsequently recognized
by the F-box protein 
 
 
 
-TRCP (Maniatis, 1999), the speci-
ficity factor of an Skp1/cullin/F-box protein ubiquitin ligase
complex (SCF) that catalyzes the covalent attachment of
polyubiquitin chains to phosphorylated 
 
 
 
-catenin. Poly-
ubiquitin conjugates of 
 
 
 
-catenin are rapidly degraded by
the proteasome (Aberle et al., 1997).
Signaling through the wnt pathway is initiated upon binding
of wnts to members of a family of seven transmembrane
receptors (frizzled receptors). Through an as yet unknown
mechanism, frizzled receptors activate a cytoplasmic protein,
dishevelled (dsh), which interacts directly with axin via their
DIX domains (Fukui et al., 2000; Julius et al., 2000; Salic et
al., 2000). The GSK3 binding protein (GBP) (Yost et al.,
1998) is recruited through its interaction with the PDZ
domain of dsh and thus brought in the proximity of axin-
bound GSK3. Binding of GBP to GSK3 inhibits its kinase
activity against 
 
 
 
-catenin, reducing its degradation by the
SCF ubiquitin ligase complex and resulting in a increased
steady state level of free 
 
 
 
-catenin.
Free 
 
 
 
-catenin interacts with the DNA binding proteins
Tcf3 and Lef1 (Behrens et al., 1996; Huber et al., 1996;
Molenaar et al., 1996) to form a bipartite transactivator that
stimulates the transcription (van de Wetering et al., 1997) of
immediate gene targets (for example, siamois [Brannon et
al., 1997] and Xnr3 [McKendry et al., 1997] in 
 
Xenopus
 
). In
the absence of 
 
 
 
-catenin, Tcf3/Lef1 proteins mediate repres-
sion when bound to the Groucho family of transcription
factor, CREB binding protein (CBP), and CtBP. Interaction
between Tcf3 and 
 
 
 
-catenin occurs at the NH
 
2
 
 terminus of
Tcf3 and is separate from the Groucho and CtBP binding
regions (for review see Barker et al., 2000).
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Models of the wnt pathway suggest a role for Tcf3/Lef1 as
an unregulated scavenger of free 
 
 
 
-catenin. However, CBP
binds and acetylates a lysine in the 
 
 
 
-catenin interaction do-
main of Tcf3, thereby lowering its affinity for 
 
 
 
-catenin
(Waltzer and Bienz, 1998). Some members of the Sox family
of HMG box proteins also bind 
 
 
 
-catenin and block its bind-
ing to Tcf (Zorn et al., 1999). In 
 
Caenorhabditis elegans
 
, com-
ponents of the mitogen-activated kinase pathway phosphory-
late Tcf-bound 
 
 
 
-catenin so as to block nuclear localization
(Rocheleau et al., 1999). These studies indicate that the inter-
action between 
 
 
 
-catenin and Tcf3 is dynamic and that regu-
lating it may play an important role in modulating wnt sig-
naling. We developed recently an in vitro system to examine
the cytoplasmic components of the wnt signaling pathway us-
ing 
 
Xenopus
 
 egg extracts (Salic et al., 2000). We have used
this system to study the effects of Tcf3 on 
 
 
 
-catenin stability
and the interaction between Tcf3 and 
 
 
 
-catenin.
Components of the wnt pathway upstream of Tcf3 regu-
late 
 
 
 
-catenin stability. However, a clear role for Tcf3 itself
in the stabilization of 
 
 
 
-catenin has not been demonstrated.
In the present study, we show that Tcf3 inhibits the interac-
tion between 
 
 
 
-catenin and axin/APC and that Tcf3 and
 
 
 
-catenin interact significantly even in the absence of wnt sig-
naling to modulate 
 
 
 
-catenin turnover. We show that GSK3
and casein kinase (CK) 1
 
 
 
 both have direct but opposite ef-
fects in regulating the 
 
 
 
-catenin–Tcf3 interaction. We also
find that a significant fraction of Tcf3 is cytoplasmic in both
 
Xenopus
 
 embryos and cultured cells, indicating that Tcf3 can
act outside the nucleus to regulate 
 
 
 
-catenin degradation.
Additionally, we provide evidence that CKI
 
 
 
 stimulates the
interaction between dsh and GBP. These results suggest two
possible mechanisms for the role of CK1
 
 
 
 in wnt signaling
and provide further evidence that regulated formation of the
 
 
 
-catenin–Tcf3 complex and the dsh–GBP complex play a
crucial role in wnt signaling.
 
Results
 
Tcf3 inhibits both 
 
 
 
-catenin degradation and 
phosphorylation by GSK3
 
To determine if Tcf3 can influence the rate of 
 
 
 
-catenin
degradation, we either translated Tcf3 mRNA in 
 
Xenopus
 
extracts (Fig. 1 A) or added purified recombinant Tcf3 to
the extracts (Fig. 1 B). In both cases, Tcf3 inhibited 
 
 
 
-cate-
nin degradation. An IC
 
50
 
 of 30 nM was determined by care-
ful titration of Tcf3 (1 nM to 1 
 
 
 
M) into 
 
Xenopus
 
 extracts
(unpublished data). As a test for the specificity of this inter-
action, we used an NH
 
2
 
-terminal deletion mutant of Tcf3,
 
 
 
NTcf3, which cannot bind 
 
 
 
-catenin in vitro (Molenaar et
al., 1996). When 
 
 
 
NTcf3 mRNA was translated in extracts,
it had no effect on 
 
 
 
-catenin degradation (Fig. 1 A); simi-
larly, 
 
 
 
NTcf3 purified protein (Fig. 1 B) had no effect.
Thus, the inhibitory effect of Tcf3 on 
 
 
 
-catenin degradation
is dependent on its ability to interact with 
 
 
 
-catenin
through the NH
 
2
 
-terminal domain. 1 
 
 
 
M of purified GSK3
(Fig. 1 B) did not reverse the inhibitory effect of Tcf3 (1
 
 
 
M) on 
 
 
 
-catenin degradation, suggesting that the effect of
Tcf3 was not due to titration of GSK3. A more careful ex-
amination showed that excess GSK3 could partially rescue
the inhibition of 
 
 
 
-catenin degradation by lower levels of
 
Tcf3 (100 nM); however, even a large excess of GSK3 did
not reverse the effect of 300 nM added Tcf3 (Fig. 1C).
Phosphorylation of 
 
 
 
-catenin by GSK3 is required for
 
 
 
-catenin degradation (Yost et al., 1996). 
 
 
 
-catenin and axin
are phosphorylated by GSK3 in vitro, and 
 
 
 
-catenin phos-
phorylation is stimulated greatly by axin (Hart et al., 1998;
Ikeda et al., 1998). We reconstituted this reaction in vitro us-
ing purified proteins and examined the effects of recombinant
Tcf3 on the kinase reaction. 5 
 
 
 
M Tcf3 strongly inhibited
 
 
 
-catenin phosphorylation by GSK3 but had no effect on the
phosphorylation of axin (Fig. 1 D). This result demonstrates
that the effect of Tcf3 on 
 
 
 
-catenin phosphorylation is not due
to titration or inhibition of GSK3 but rather to the sequestra-
tion of 
 
 
 
-catenin, preventing its interaction with axin/GSK3.
 
Tcf3 and axin/APC compete for 
 
 
 
-catenin binding
 
Phosphorylation and subsequent degradation of 
 
 
 
-catenin
requires its association with both APC and axin. Since bind-
ing of Tcf3 to 
 
 
 
-catenin blocks its degradation, we tested if
this is due to blocking binding of 
 
 
 
-catenin to axin and/or
APC. As shown in Fig. 2 A, purified his-tagged Tcf3 but not
his-tagged 
 
 
 
NTcf3 blocked binding of 
 
 
 
-catenin to axin
beads. However, Tcf3 had no effect on GSK3 binding to
Figure 1. Tcf3 blocks  -catenin degradation in extracts and phos-
phorylation in vitro. (A) Translated Tcf3 but not  NTcf3 mRNA 
inhibits  -catenin degradation in extracts. (B) Purified Tcf3 protein 
(1  M) blocks  -catenin degradation. This effect was not reversed 
by 1  M GSK3. Purified  NTcf3 (1  M) does not block  -catenin 
degradation. (C) Inhibition of  -catenin degradation by lower (100 
nM) Tcf3 levels can be partially rescued by GSK3; higher Tcf3 (300 
nM) levels cannot be rescued by even a large GSK3 excess. (D) Tcf3 
inhibits the phosphorylation of  -catenin by GSK3 and axin in a 
purified system. In the same reaction, axin phosphorylation by 
GSK3 is not affected by Tcf3.Tcf controls  -catenin stability | Lee et al. 985
axin (unpublished data). A purified 100-kD fragment of
APC (APCm3) that spans the axin and  -catenin binding
sites stimulates binding of  -catenin to axin beads (Fig. 2
B). In the presence of 100 nM APCm3, addition of up to 1
 M Tcf3 protein had no detectable effect on the binding of
 -catenin to axin beads. Furthermore, binding of  -catenin
to Tcf3 beads (Fig. 2 C) is effectively inhibited in the pres-
ence of 1  M APCm3. Consistent with a dominant effect of
APC in Xenopus extracts, a majority of the soluble  -catenin
is in anti-APC immunoprecipitates (Salic et al., 2000). In
extracts, 1  M of added Tcf3 released radiolabeled  -cate-
nin from APC immunoprecipitates (Fig. 2 D). As a control,
1  M  NTcf3 had no detectable effect on  -catenin bind-
ing to endogenous APC. These results indicate that Tcf3
competes with both axin and APC for  -catenin binding.
The failure of Tcf3 to block  -catenin binding to axin in the
presence of APCm3 highlights the strong effect of APC in
driving the degradation of free  -catenin by promoting its
binding to axin and in inhibiting competing reactions
driven by Tcf3. In contrast, the ability of Tcf3 to compete
effectively with endogenous APC for  -catenin probably re-
flects the fact that most of  -catenin is not in a complex
with axin/APC, since cellular axin levels are very low (10–20
picomolar; unpublished data).
The degradation and binding data suggest that the interac-
tion between  -catenin and Tcf3 could play an important
role in vivo in regulating the degradation kinetics of  -cate-
nin. To test if this is the case in vivo, we set out to generate a
mutant of  -catenin that is unable to interact with Tcf3.
 -catenin COOH-terminal truncation mutants are shown
schematically in Fig. 2 E. One would predict that a mutant of
 -catenin that cannot interact with Tcf3 would be unrespon-
sive to added Tcf3 and would be degraded at a faster rate
than wild-type  -catenin due to its inability to interact with
endogenous Tcfs. Constructs were first tested in our degrada-
tion assay in Xenopus extracts. Full-length  -catenin and
 -catenin C2 were degraded similarly (Fig. 2 F);  -cat-
enin C1 also behaved identically to the full-length protein
(unpublished data). Degradation of full-length  -catenin and
 -catenin C2 was stimulated by axin (Fig. 2, F and G) and
inhibited by lithium (unpublished data), dishevelled (Fig. 3
A), and APCm3 (unpublished data). Mutating the GSK3
phosphorylation sites (serine to alanine) in the NH2-terminal
region of  -catenin C1 and  -catenin C2 stabilized these
proteins against degradation in extracts (unpublished data),
further demonstrating that the stability of  -catenin C1 and
 -catenin C2 is regulated similarly to wild-type  -catenin.
In contrast to  -catenin C1 and  -catenin C2,   -cat-
enin C3 was completely stable (Fig. 2 F), even when 20 nM
axin was added to extracts (which normally accelerates
the rate of wild-type  -catenin degradation greater than four-
fold) (Salic et al., 2000). The stability of  -catenin C3 is
likely due to its inability to bind axin (unpublished data), an
interaction absolutely required for  -catenin degradation
Figure 2. Tcf3 competes with axin/APC 
for  -catenin (cold competitors were 
present at 1  M in all experiments). (A) 
Binding of  -catenin to axin beads is 
inhibited by Tcf3 but not by  NTcf3. In 
contrast, binding of the  -catenin  C2 
mutant to axin is unaffected by Tcf3. (B) 
Tcf3 blocks the binding of  -catenin to 
axin beads, whereas APCm3 reverses this 
effect of Tcf3. (C) APCm3 inhibits the 
binding of  -catenin to Tcf3 beads. (D) 1 
 M his6-TCF3 blocks the interaction of 
 -catenin with endogenous APC in 
extracts, whereas his6- NTcf3 has no 
effect. (E) Scheme of the COOH-terminal 
 -catenin deletion constructs used to 
map the fragment of  -catenin responsible 
for stabilization by Tcf3. (F) Normal and 
axin-induced degradation of  -catenin, 
 -catenin C2, and  -catenin C3 in 
Xenopus extracts.  -catenin C3 is 
completely stable and does not respond 
to axin. (G) Axin stimulates the turnover 
of both  -catenin and  -catenin C2 in 
the same degradation reaction. (H) 
 -catenin and  -catenin C2 both bind to 
APC and binding is not disrupted by the 
Tcf4 NH2-terminal peptide or by the 
cat449/645 fragment (at  2  M).986 The Journal of Cell Biology | Volume 154, 2001
(Behrens et al., 1998; Hart et al., 1998; Ikeda et al., 1998;
Itoh et al., 1998). Interestingly, degradation of  -catenin C2
is not inhibited by up to 1  M Tcf3 (Fig. 3 A), consistent
with its inability to bind Tcf3 (Fig. 3 C).  -catenin C2
still binds axin (Fig. 3 C). As with  -catenin, radiolabeled
 -catenin C2 binds APC in vitro (Fig. 2 H) and can be im-
munoprecipitated from Xenopus extracts using anti-APC anti-
body beads (unpublished data). However, unlike full-length
 -catenin, this interaction is not blocked by 1  M Tcf3
added to the extracts (unpublished data). When compared
with wild-type  -catenin,  -catenin C2 has a significantly
faster degradation rate (Fig. 3, A and B), suggesting that en-
dogenous Tcf3 regulates the rate of  -catenin turnover.
The interaction of Tcf3 with  -catenin controls the rate 
of  -catenin turnover in vitro and in vivo
To explore further the possibility that  -catenin degradation
is normally inhibited by its interaction with Tcf3, we asked
if perturbing this interaction would affect  -catenin degra-
dation in vivo and in extracts. We first developed an inhibi-
tor of this interaction. Based on our deletion analysis, a frag-
ment of  -catenin (amino acids 449–645, cat449/645)
between the COOH termini of  -catenin C1 and  -cat-
enin C2 was expressed as a maltose-binding protein (MBP)
fusion and tested for its ability to block the binding of
 -catenin to Tcf3 beads. Excess cold  -catenin and cat449/
645 (2  M each) compete equally well with radiolabeled
 -catenin for binding to Tcf3-beads (Fig. 3 D). In contrast
to full-length  -catenin, cat449/645 does not compete for
binding of axin to  -catenin beads, indicating that the frag-
ment selectively interferes with the  -catenin–Tcf3 interac-
tion. Lower than 2- M levels of cat449/645 do not affect
binding of  -catenin to APC (Fig. 2 H); however, higher
cat449/645 concentrations can significantly inhibit binding
to APC, suggesting some overlap between the Tcf3 and the
APC binding sites on  -catenin.
Since cat449/645 below 2  M blocks the interaction be-
tween  -catenin and Tcf3 without affecting the interaction
between  -catenin and axin and APC, we tested its effect on
the rate of  -catenin degradation. Addition of 200 nM
MBP-cat449/645 to Xenopus extracts accelerated the rate of
 -catenin degradation by  50% (Fig. 3 E). Similarly, when
injected into Xenopus embryos cat449/645 stimulated the
degradation of coinjected  -catenin–luciferase by  70%
(Fig. 3 F). Paradoxically, high concentrations ( 2  M) of
cat449/645 inhibited  -catenin degradation (unpublished
data), probably reflecting the ability of high concentrations
of this mutant to compete with wild-type  -catenin for
binding to APC (Fig. 3 D). However, in the concentration
range of cat449/645 where the  -catenin–APC interaction
is not affected, the mutant blocks the Tcf– -catenin binding
and stimulates  -catenin turnover.
The NH2-terminal regions of Tcf3 and Tcf4 contain a
conserved   -catenin binding domain (Molenaar et al.,
1996). We wanted to determine if a peptide corresponding
to the NH2-terminal region of Tcf4 could similarly disrupt
the interaction between  -catenin and Tcf3. A human Tcf4
NH2-terminal peptide blocked the binding of  -catenin to
Tcf3 beads (Fig. 4 A). As for cat449/645, the Tcf4 NH2-ter-
minal peptide had no effect on the interaction between
 -catenin and axin (Fig. 4 B) or on the interaction between
 -catenin and APC (Fig. 2 H). Addition of the Tcf4 NH2-
terminal peptide to Xenopus extracts stimulated the degrada-
tion of  -catenin by  65% (Fig. 4 C), further demonstrat-
Figure 3. Effects of Tcf3 on  -catenin 
mutants. (A) Degradation of both  -cat-
enin and  -catenin C2 is inhibited by
1  M dsh, but only  -catenin is inhibited 
by 1  M Tcf3. (B) Graphical representa-
tion of densitometry measurements of the 
autoradiogram in A shows the faster deg-
radation rate of  -catenin C2 compared 
with  -catenin. (C) Both  -catenin and 
 -catenin C2 bind to axin, but only 
 -catenin binds to xTcf3 in vitro. (D) 
MBP-cat449/645 inhibits by  95% the 
binding of [
35S]methionine-labeled 
 -catenin to Tcf3 in vitro (ii). MBP-
cat449/645 (2  M) had no effect on the 
binding of axin to  -catenin beads (i) and 
a moderate effect on the binding of 
 -catenin to APC beads (iii). Binding of 
radiolabeled  -catenin and axin to con-
trol beads was negligible. (E) Degradation 
of radiolabeled  -catenin in Xenopus 
extracts is stimulated by MBP-cat449/645 
(200 nM). (F)  -catenin–luciferase is 
degraded more rapidly in embryos when 
coinjected with MBP-cat449/645.  -cat-
enin–luciferase (4 ng) protein was in-
jected into 2-cell stage Xenopus embryos 
with or without MBP-cat449/645 (4 ng). 
At the indicated times, embryos were 
processed for luciferase assays.Tcf controls  -catenin stability | Lee et al. 987
ing that Tcf proteins are normally involved in modulating
 -catenin degradation. A control peptide had no effect on
the degradation of  -catenin (unpublished data).
Although we have demonstrated that Tcf proteins can reg-
ulate the rate of  -catenin degradation, if Tcf and the pro-
teins involved in  -catenin turnover do not normally colocal-
ize in the cell such a mechanism might not be physiological.
Specifically, Tcf is a transcription factor that may reside ex-
clusively in the nucleus, whereas  -catenin degradation may
occur solely in the cytoplasm. Therefore, we measured the
amount of cytoplasmic and nuclear Tcf in Xenopus eggs, stage
7.5  Xenopus embryos, and cultured human 293 cells. As
shown in Fig. 5 B, the vast majority of Tcf is cytoplasmic in
eggs. Even in stage 7.5 embryos where the number of nuclei is
 2,000 per embryo (versus one per egg), a large fraction of
Tcf is cytoplasmic (Fig. 5 A; 70% cytoplasmic fraction versus
30% in the nuclear fraction). We found a similar distribution
of myc6-tagged xTcf3 protein in stage 7.5 embryos that were
injected with myc6-tagged xTcf3 mRNA at the 2-cell stage.
These findings are perhaps not surprising and may reflect two
conditions found in a developing embryo: (a) the low nucleo-
cytoplasmic ratio of the embryonic cells and (2) the rapid di-
vision cycles of the early embryo (30 min per cycle), which re-
sults in disassembly of the nucleus for half of the time. These
two situations allow ample opportunity for Tcf to interact
with cytoplasmic  -catenin to regulate its degradation. We
next wanted to determine whether or not the high level of cy-
toplasmic Tcf protein was unique to Xenopus embryos and ex-
amined the cytoplasmic pool of Tcf in cultured cells. As
shown in Fig. 5, C and D, fractionation of 293 cells indicates
that  40% of Tcf was cytoplasmic (compared with topo-
isomerase II, which is quantitatively pelleted with the nuclei).
Therefore, in cultured 293 cells a significant amount of Tcf is
present in the cytoplasm and thus capable of competing with
APC and axin for  -catenin binding.
Tcf3 phosphorylation by GSK3 and CK1 
We noted during the characterization of recombinant his-
tidine-tagged Tcf3 (his6-Tcf3) purified from baculovirus-
infected Sf9 cells that certain preparations exhibited kinase
activity, resulting in a phosphorylated form of Tcf3 that
comigrated with the unphosphorylated form by SDS-
PAGE. Furthermore, addition of recombinant his6-GSK3
to the reaction enhanced the phosphorylation of Tcf3 (un-
published data). Phosphorylation of Tcf3 was suppressed
by 100 mM LiCl (a direct inhibitor of GSK3) (Klein and
Melton, 1996) to the reaction (Fig. 6 A), which suggested
that endogenous GSK3 copurified with recombinant his6-
Tcf3 from Sf9 cells. This was confirmed by Western analy-
Figure 4. Effects of an NH2-terminal Tcf4 
peptide on  -catenin stability and rate of 
axin– -catenin dissociation. (A)  -catenin 
binding to xTcf3 beads is inhibited by an 
NH2-terminal Tcf4 peptide (10  M). (B) In 
contrast,  -catenin binding to axin is unaf-
fected by the presence of the NH2-terminal 
Tcf4 peptide but is blocked by cold Tcf3. 
(C) Addition of the NH2-terminal Tcf4 pep-
tide (2  M) to Xenopus extracts stimulates 
 -catenin degradation, which is in contrast 
to the inhibitory effect of Tcf3 (500 nM). (D) 
Half-life of the axin– -catenin complex. Ra-
diolabeled  -catenin bound to axin beads 
(in the presence or absence of 100 nM APC) 
was incubated with buffer, cold Tcf3 (2  M) 
or cold  -catenin (2  M) at room tempera-
ture. The  -catenin remaining on beads was 
measured as a function of time.
Figure 5. A significant fraction of total cellular TCF protein in 
Xenopus embryos and in cultured cells is nonnuclear. (A) Both cells 
of 2-cell embryos were injected with myc6-Tcf3 RNA (250 pg/
blastomere), gently homogenized at stage 7.5 (lysate), and centrifuged 
to pellet the nuclei (Sup). Equivalent volumes of lysate and supernatant 
were subsequently processed for Western analysis using an anti-
myc antibody. Most of the detected myc-tagged Tcf3 is present in 
the supernatant fraction. (B) Xenopus eggs and stage 7.5 embryos 
were processed as described for the myc6-Tcf3 RNA injected 
embryos except that an anti-Tcf antibody was used to detect 
endogenous Tcf. Nearly all of the Tcf detected is present in the 
supernatant fraction of eggs in contrast to stage 7.5 embryos. Lysates 
and supernatants were stained with Hoechst to confirm the 
presence (lysates) or absence (supernatants) of intact nuclei (unpub-
lished data). Nuclear and cytoplasmic preparations from cultured 
293 cells were blotted for topoisomerase II (C) and Tcf and stained 
with Hoechst (D). The nuclear pellet was brought to the same 
volume as the cytoplasmic fraction, and equivalent volumes were 
used for Western analysis.988 The Journal of Cell Biology | Volume 154, 2001
sis using an anti-GSK3 antibody (unpublished data). To
rule out the possibility that GSK3 gratuitously copurified
with Tcf3 on the Ni
2  beads (which have ion exchange
properties), we tested whether Tcf3 beads could be used to
purify GSK3 from Xenopus extracts. We found that Tcf3
beads but not control BSA beads were capable of purifying
GSK3 from Xenopus extracts (Fig. 6 B). No GSK3 was
eluted from Tcf3 beads that were not preincubated in Xe-
nopus extracts, which ruled out the possibility that the
eluted GSK3 originated from Sf9 cells during the purifica-
tion of Tcf3.
CK1  was demonstrated recently to be a positive regulator
of wnt signaling (Peters et al., 1999; Sakanaka et al., 1999).
Although these studies suggested physical associations be-
tween CK1  and both axin (Sakanaka et al., 1999) and dsh
(Peters et al., 1999; Sakanaka et al., 1999), the mechanism
of action of CK1  in wnt signaling has not been determined.
A dominant negative dsh mutant (Xdd1) that lacks the puta-
tive CK1  binding domain (PDZ domain) fails to block the
ability of CK1  to stimulate wnt signaling in vivo (Sokol,
1996), a result inconsistent with a model in which CK1 
mediates wnt signaling by binding to the PDZ domain of
dsh. An analysis of the primary sequence of Tcf3 indicates
that it contains multiple potential phosphorylation sites for
both GSK3 and CK1 . Furthermore, many of the phos-
phorylation sites for GSK3 and CK1  are overlapping and
are conserved within the Tcf family.
We examined the interaction of GSK3 and CK1  with
Tcf3. Radiolabeled GSK3 and CK1  both significantly
bound Tcf3 beads (Fig. 6, C and D). Furthermore, the
binding sites of GSK3 and CK1  on Tcf3 appear to be dis-
tinct from one another, since GSK3 binding cannot be com-
peted with excess cold CK1 . Conversely, the binding of
CK1  to Tcf3 beads is not abolished when incubated with
excess cold GSK3. As with GSK3, CK1  can phosphorylate
recombinant Tcf3 in vitro. CK1  can enhance the phos-
phorylation of Tcf3 in an in vitro kinase assay above the
level due to that of contaminating GSK3 (Fig. 6 E). Further-
more, the enhanced Tcf3 phosphorylation by CK1  is par-
tially inhibited when CKI-7 (IC50, 10–30  M; purchased
from Seikagaku Corporation), a selective inhibitor of CK1
activity (Chijiwa et al., 1989), is included in the kinase reac-
tion. The association between Tcf3 and GKS3/CK1  repre-
sents bona fide in vivo interactions, since both endogenous
Xenopus GSK3 and CK1e immunoprecipitated with an anti-
myc antibody from extracts made from embryos injected
with myc6-xTcf3 mRNA (Fig. 6 F). Although Tcf3 binds
GSK3, it does not inhibit the activity of GSK3 against axin
(Fig. 1 D).
Effects of Tcf3 phosphorylation on its activity
These experiments establish that both GSK3 and CK1  can
bind and phosphorylate Tcf3 and suggest a possible role for
both GSK3 and CK1  in modulating Tcf3 activity. We
therefore tested if these kinases affect the interaction of Tcf3
with  -catenin. Tcf3 can inhibit the degradation of  -cate-
nin (Fig. 1, A and B). CK1  and Tcf3 act synergistically to
inhibit  -catenin degradation: as shown in Fig. 7 A, concen-
trations of CK1  and Tcf3 that by themselves are not inhib-
itory together cause significant inhibition of  -catenin deg-
radation. In addition, CKI-7 blocks the effect of Tcf3 in a
dose-dependent manner in Xenopus extracts (Fig. 7 B). As
expected, 100  M CKI-7 (even in the presence of 10 nM
Tcf3) actually accelerates the rate of degradation of  -cate-
nin in extracts compared with a buffer control. Thus, CK1 
activity is required for inhibition of  -catenin degradation
by Tcf3. The simplest model consistent with these experi-
mental results is that phosphorylation of Tcf3 by CK1  pro-
motes the interaction of Tcf3 with  -catenin. As shown in
Fig. 7 C, preincubation of Tcf3 beads with CK1  increases
their affinity for  -catenin nearly fourfold compared with
Figure 6. GSK3 and CK1  bind and phosphorylate Tcf3. (A) Tcf3 
purified from Sf9 cells contains lithium-sensitive kinase activity. 
Recombinant his6-Tcf3 (1 g) was incubated in 10  l kinase buffer 
(described in Materials and methods) for 30 min at room temperature 
either in the presence or absence of 100 mM LiCl, which normally 
inhibits GSK3 activity. Phosphorylation of Tcf3 is dramatically 
decreased in the presence of lithium. (B) Tcf3 beads pull down 
GSK3 from Xenopus extracts. Beads (control-BSA or Tcf3-coupled) 
were incubated with Xenopus egg extracts, washed, eluted, and 
analyzed by Western blotting with a monoclonal anti-GSK3 anti-
body. (C) Both GSK3 and CK1  bind Tcf3. Radiolabeled in vitro–
translated GSK3 and CK1  bind Tcf3 beads. Binding of radiolabeled 
GSK3 and CK1  to Tcf3 beads was abolished by addition of excess 
cold protein (5  M of his6-GSK3 and MBP-CK1 , respectively), 
demonstrating specificity of the binding reaction. However, excess 
cold his6-GSK3 does not block CK1  binding to Tcf3, whereas 
excess cold MBP-CKI  fails to block GSK3 binding to Tcf3, which 
suggests the existence of independent nonoverlapping sites for 
GSK3 and CK1  binding on Tcf3. (D) CK1  can phosphorylate Tcf3. 
Incubating Tcf3 with MBP-CK1  enhances its phosphorylation. 
Endogenous kinase activity seen for Tcf3 alone reflects copurification 
of GSK3. (E) The enhancement of Tcf3 phosphorylation by CK1  can 
be readily reversed by addition of CKI-7 (100  M), a specific CK1 
inhibitor, which indicates that Tcf3 is a substrate for both GSK3 and 
CK1 . (F) Both GSK3 and CK1  coimmunoprecipitates with myc-
tagged Tcf3. Both cells of 2-cell embryos were injected with 
myc6-Tcf3 RNA (500 pg/blastomere), homogenized at stage 7.5, 
and precipitated with either anti-myc antibodies coupled to beads 
or to control beads. Western blotting with antibodies against GSK3 
and CK1e indicates that both proteins coimmunoprecipitates with 
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untreated beads. Furthermore, although preincubating Tcf3
beads with GSK3 had very little effect on  -catenin binding,
GSK3 abolished the effect of CK1 . One prediction from
these experiments is that blocking GSK3 activity would fur-
ther potentiate the effect of CK1 . As expected, GBP acts
synergistically with CK1  to inhibit  -catenin degradation
(Fig. 7 D). Failure of GSK3 to inhibit the effects of Tcf3 in
our earlier experiments (Fig. 1 B) was probably due to the
high concentration of Tcf3 (1  M) used. In fact, the effect
of adding Tcf3 at concentrations closer to its IC50 for  -cat-
enin degradation (100 nM) can be reversed by the addition
of 1  M GSK3 (Fig. 1 C).
In previous studies, injections of CKI-7 did not block the
effects of overexpressed  -catenin in Xenopus embryos (Pe-
ters et al., 1999), which suggested that CK1  acts upstream
of  -catenin. However, it is unclear whether or not epistasis
experiments performed by injecting components of the wnt
pathway upstream of  -catenin (wnt and dsh) can boost the
high level of  -catenin readily obtained by direct injection of
 -catenin mRNA. It should be noted that the concentrations
of CKI-7 used in our in vitro experiments is 10-fold greater
than in these experiments and is still only sufficient to inhibit
50% of the CK1 activity. We found that injection of compa-
rable concentrations of CKI-7 into Xenopus embryos were
toxic and arrested cell division soon after injection.
Role of CK1  in mediating dsh activity
Given the fact that CK1  has been shown to bind axin (Sa-
kanaka et al., 1999) and dsh (Peters et al., 1999), it appears
that CK1  like GSK3 simultaneously affects many compo-
nents of the wnt pathway. Dsh acts synergistically with
CK1  in Xenopus embryos (Fig. 8 A). Embryos injected ven-
trally at the 4–8-cell stage with low doses of Dsh (100 pg) or
CK1  (50 pg) RNA develop normally (100%, n   30),
whereas injection of embryos with both Dsh and CK1  re-
sulted in axis duplication (68%, n   50). Dsh acts synergis-
tically with CK1  to inhibit  -catenin degradation in Xeno-
pus extracts (Fig. 8 B), consistent with the in vivo results.
Preliminary experiments indicate that both GSK3 and
CK1  can bind the PDZ domain of dsh (unpublished data).
Since GBP binds the PDZ domain of dsh, we tested whether
CK1  or GSK3 can alter the affinity of dsh for GBP. CK1 
stimulates the binding of radiolabeled dsh to GBP in Xeno-
pus extracts four- to fivefold greater than in buffer- or
GSK3-treated extracts (Fig. 8 C). This result indicates that
in addition to promoting the association between Tcf3 and
 -catenin, CK1  stimulates the binding of GBP to dsh. In-
terestingly, in the absence of Xenopus extracts CK1  has no
effect on binding of dsh to GBP, suggesting that extracts
contain an activity that mediates the effect of CK1  on the
dsh–GBP interaction.
Discussion
We have demonstrated both in vivo in Xenopus embryos and
in vitro in Xenopus egg extracts that Tcf3 inhibits the rate of
 -catenin degradation in a dose-dependent manner. We
show that the inhibition of  -catenin degradation by Tcf3
protein has physiological relevance, since a significant frac-
tion of the total Tcf protein resides in the cytoplasm in Xe-
nopus eggs and early embryos and in cultured 293 cells.
Thus, Tcf can effectively compete with the degradation ma-
chinery (axin/APC/GSK3 complex) for  -catenin binding.
The inhibitory effect of Tcf3 depends on its ability to
bind  -catenin because an NH2-terminal deletion mutant
of Tcf3 that lacks the  -catenin binding site has no effect
on   -catenin degradation. A  -catenin COOH-terminal
deletion mutant ( -catenin C2) is regulated in a manner
indistinguishable from the wild-type protein except it is no
longer sensitive to Tcf3 and is degraded at a faster rate than
Figure 7. Effect of CK1  on Tcf3–
 -catenin interaction. (A) Tcf3 and 
CK1  act synergistically to inhibit 
 -catenin degradation. His6-Tcf3 (3 nM) 
and MBP-CK1  (200 nM) were added to 
Xenopus extracts either alone or to-
gether. Inhibition of  -catenin degrada-
tion is dramatically enhanced by addition 
of both Tcf3 and CK1  (nearly 80% re-
maining after 3 h) compared with addi-
tion of either Tcf3 or CK1  alone (35% 
remaining after 3 h). (B) The CK1  inhibi-
tor CKI-7 inhibits the effect of Tcf3 or 
 -catenin stabilization. CKI-7 inhibits 
the effects of 10 and 30 nM Tcf3 in a 
dose-dependent manner. At high CKI-7 
concentrations (100  M), the effect of 
Tcf3 is abolished and  -catenin degra-
dation is actually stimulated when 
compared with the buffer control. (C) 
CK1  stimulates the binding of Tcf3 to 
 -catenin. Preincubation of Tcf3 beads 
with 1  M CK1  in kinase buffer stimu-
lates its binding to  -catenin (compared with preincubation in buffer alone). This effect of CK1  was decreased by addition of 1  M GSK3 to 
the kinase reaction. GSK3 by itself had no effect on the binding of Tcf3 to  -catenin. A nearly fivefold increase in the binding of Tcf3 to 
 -catenin is seen when Tcf3 beads were preincubated with CK1 . (D) CK1  acts synergistically with GBP to inhibit  -catenin degradation. 50 
nM GBP or 200 nM CK1  has no effect on  -catenin degradation; however, together they dramatically inhibit  -catenin degradation in extracts.990 The Journal of Cell Biology | Volume 154, 2001
the full-length protein in Xenopus extracts. Based on experi-
ments with this mutant, we defined a fragment of  -cate-
nin (cat449/645) that can disrupt the interaction between
 -catenin and Tcf but not the interaction of  -catenin with
axin/APC. Addition of this purified fragment accelerates the
rate of  -catenin degradation in both Xenopus extracts and
embryos. Similarly, a peptide encoding the NH2-terminal
 -catenin binding region of Tcf4 (which also blocks the
binding of  -catenin to Tcf3) stimulates  -catenin degrada-
tion. Our attempts to determine whether this peptide has
any effect on axis formation have been unsuccessful because
injections of this peptide into Xenopus embryos at concen-
trations sufficient to block Tcf3– -catenin interaction se-
verely perturbed gastrulation. Although the effects of the
Tcf4 peptide and the cat449/645 fragment might seem
modest, these results should be viewed in the context of the
effects of known regulators of the wnt pathway (for exam-
ple, axin and dsh), which alter the rate of  -catenin degra-
dation only three- to fourfold.
Structure-function analysis of  -catenin (von Kries et al.,
2000) and the x-ray crystal structure of its complex with the
 -catenin binding domain of Tcf3 (Graham et al., 2000) in-
dicate that the Tcf/Lef1 binding site of  -catenin forms a
positively charged groove. This interacts with the  -catenin
binding domain of Tcf3 consisting of an extended structure
that can be divided into three sites. A comparison of this
structure to  -catenin C2 indicates that this mutant is
missing one of the flanking regions and part of the central
region involved in Tcf– -catenin interaction.
Our results suggest that cytoplasmic Tcf3 competes for
 -catenin binding with both APC and axin (Fig. 8 A); how-
ever, once a trimeric complex consisting of  -catenin, axin,
and APC is formed Tcf3 is unable to compete effectively for
 -catenin binding (Fig. 2 B). By sequestering  -catenin in
the cytoplasm or enhancing its export from the nucleus
(Henderson, 2000), APC inhibits signaling through the wnt
pathway by further blocking assembly of the  -catenin–
Tcf3 bipartite complex. Therefore, in the absence of APC
the effect of Tcf proteins on wnt signaling would predomi-
nate. Loss of APC function would not only result in an in-
crease in the amount of free  -catenin available to bind Tcf3
but would also allow Tcf3 to compete effectively with axin
for  -catenin binding.
Factors that change the concentration of Tcf3 protein or
its affinity for  -catenin can alter the amount of the  -cate-
nin–Tcf complex. Decreases or increases in the ratio of solu-
ble  -catenin to Tcf3 can modulate the transcription level of
target genes, since Tcf3 acts as a transcriptional repressor in
the absence of  -catenin and as a transcriptional activator
when bound to  -catenin (Cavallo et al., 1998; Roose et al.,
1998). A model of the wnt pathway in which the level of sig-
naling is continually being modulated (rather than simply
being in the “on” or “off” position) is an attractive one. In
fact, experiments in which cells have been transfected with
axam (Kadoya et al., 2000), an axin binding protein that
blocks its interaction with dsh, show a reduced level of
 -catenin. This result indicates that even in the absence of
ligand a significant amount of signal modulation occurs in
the wnt pathway.
A major mechanism by which the rate of  -catenin degra-
dation is regulated by a wnt ligand is through its control of
GSK3 kinase activity (Fig. 8 B). Previous studies of GSK3
have indicated that it controls nearly every level of  -catenin
degradation: (a) phosphorylation of APC to facilitate its in-
teraction with  -catenin, (b) phosphorylation of axin to pro-
mote its stability and possibly to increase its affinity for
 -catenin, and (c) phosphorylation of  -catenin so as to allow
recognition by the SCF ubiquitin ligase complex. Studies us-
ing promoter-based assays to assess the activation state of the
wnt pathway have found disparities between the steady-state
levels of  -catenin and the transcriptional activation of re-
porter constructs. Using a biochemical approach, we have
revealed an additional role for GSK3 in the wnt pathway
that may account for these discrepancies: GSK3 phosphory-
lates Tcf3 thereby decreasing its affinity for  -catenin and
antagonizing the activity of CK1 . This model helps explain
why insulin growth factor (IGF) 1 can enhance the stability
Figure 8. Role of CK1  in mediating dsh activity. (A) dsh acts syner-
gistically with CK1  in Xenopus embryos to induce axis duplication. 
Embryos were injected with 50 pg CK1 , 100 pg dsh, or 50 pg CK1  
plus 100 pg dsh RNA in one ventral blastomere of 4–8-cell stage 
embryos. (B) Dsh and CK1e act synergistically to inhibit  -catenin 
degradation. Dsh protein (100 nM) and CK1e protein (500 nM) were 
added to extracts alone or in combination. (C) GBP cross-linked 
beads were incubated with radiolabeled dsh and either buffer, 1  M 
CK1 , or 1  M GSK3 in the presence or absence of Xenopus extracts. 
CK1  stimulates the binding of GBP to radiolabeled dsh in Xenopus 
extracts. No differences were detected when binding was performed 
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of   -catenin but not transcriptional activation of down-
stream targets (Playford et al., 2000), whereas addition of
the GSK3 inhibitor lithium resulted in a dramatic increase
in  -catenin–Tcf–mediated transcriptional activation. IGF-1
promotes the stability of  -catenin by stimulating its tyro-
sine phosphorylation without affecting the activity of GSK3.
Increases in  -catenin levels mediated by IGF-1 may not be
sufficient to overcome the inhibitory effect of GSK3 on
 -catenin–Tcf interaction. It will be interesting to explore
the biochemical state of Tcf in early Xenopus development
and its contribution to wnt signaling, particularly the role of
its interactions with GSK3 and CK1 .
Our initial experiments indicated that GSK3 does not
readily reverse the inhibitory effect of Tcf3 at high concen-
tration (1  M), but subsequent experiments revealed that
GSK3 reverses the effect of Tcf3 at lower concentrations
that are close to the IC50 of Tcf3 for  -catenin degradation.
These conflicting results demonstrate the subtleties of these
experiments and the hazards inherent in overexpression
studies and highlight the advantages of using a biochemical
system to study the wnt pathway. The concentrations of in-
dividual components can be manipulated so as to reveal reg-
ulations that might otherwise be overlooked in experiments
involving overexpression of components by transfection of
DNA into cultured cells or injection of RNAs into embryos.
CK1  is both necessary and sufficient for wnt signaling (Pe-
ters et al., 1999; Sakanaka et al., 1999). Our results suggest
that one of the roles of CK1  in wnt signaling is to phos-
phorylate Tcf3 thereby increasing its affinity for  -catenin.
In Xenopus extracts, CK1  and Tcf3 synergize to inhibit
 -catenin degradation. Studies with the CK1  inhibitor
CKI-7 (Fig. 6 C) indicate that CK1  regulates the formation
of the  -catenin–Tcf3 complex: CKI-7 blocks the inhibitory
effect of Tcf3 on  -catenin degradation and therefore in-
creases the rate of  -catenin degradation above basal levels.
The mechanism by which GSK3 and CK1  oppose each
other’s actions is not known. Intriguingly, our analysis of the
crystal structure of  -catenin complexed with the  -catenin
binding domain of Tcf3 (Graham et al., 2000) indicates that
one of the three  -catenin binding regions of Tcf3 (amino ac-
ids 49–64 of Xenopus Tcf3) contains a conserved and overlap-
ping phosphorylation site for both GSK3 and CK1  (which is
also present in other members of the Tcf/LEF-1 family that
bind  -catenin). This may indicate that binding and/or phos-
phorylation of Tcf3 by one kinase may preclude the binding
and/or phosphorylation of Tcf3 by the other kinase.
The interaction between  -catenin and Tcf appears to be
regulated in multiple ways. In Drosophila, the CBP acetylates
a lysine in the  -catenin binding domain of dTcf, thereby
lowering its affinity for  -catenin (Waltzer and Bienz, 1998).
However, in vertebrates CBP has been shown to bind to the
COOH-terminal region of  -catenin to activate Tcf-medi-
ated gene transcription (Takemaru and Moon, 2000). Cer-
tain Sox proteins have been shown to interact with  -catenin
and block its interaction with Tcf proteins (Zorn et al.,
1999). ICAT, a  -catenin interacting protein inhibits the in-
teraction of  -catenin with Tcf4 and represses  -catenin–
Tcf4–mediated gene transcription (Tago et al., 2000). In C.
elegans, the LIT-1 protein phosphorylates POP-1, a Tcf/
LEF-related protein, to downregulate its activity (Rocheleau
et al., 1999). Interestingly, phosphorylation of POP-1 re-
quires an active LIT-1 kinase complex containing WRM-1, a
 -catenin–like homologue belonging to a divergent wnt
pathway. Finally, the bipartite  -catenin–Tcf complex can
directly bind Smad4 to stimulate expression of a target gene,
twin (Nishita et al., 2000). Each of these interactions could
also modulate  -catenin stability, leading to pleiotropic and
often synergistic effects in wnt signaling. Similarly to GSK3,
CK1  appears to regulate the wnt pathway at more than one
level. CK1  stimulates the binding of dsh to GBP in Xenopus
extracts. Although CK1e can directly bind dsh, the mecha-
nism by which CK1  promotes dsh–GBP interaction is not
clear, since this effect of CK1  was only detected in the pres-
ence of Xenopus extracts. Interestingly, the amount of dsh
bound to GBP in the presence of Xenopus extracts was much
less than the amount of dsh bound to GBP in the absence of
extracts. Dsh is heavily phosphorylated in Xenopus extracts
(unpublished data), which possibly inhibits its binding to
GBP. Addition of CK1  to Xenopus extracts increases the
binding of dsh to GBP to levels comparable to that seen in
the absence of extract. These results suggest the existence of
an as yet unidentified factor(s) that functions to inhibit the
binding of GBP to dsh; one role of CK1  may be to counter-
act the activity of this factor.
Both Tcf and  -catenin are required for axis formation in
Xenopus development.  -catenin is stabilized on the dorsal
side of the embryo during early development, and when zy-
gotic transcription starts at the midblastula transition,  -cate-
nin translocates into the nuclei of dorsal cells. How  -catenin
stabilization and nuclear translocation on the dorsal side takes
place is still unclear, although both processes are perhaps es-
sential for axis formation. Regulation of  -catenin stability by
Tcf might play an important role in these processes.
Materials and methods
Egg extracts
Xenopus egg extracts were prepared as described previously using a modi-
fied version of a method used for making cell cycle extracts (Salic et al.,
2000). Centrifugation was performed at 4 C in a microfuge. After a packing
spin (30 s at 30 g), the eggs were crushed at 21,000 g for 5 min. The cyto-
plasmic layer was removed and spun two more times at 21,000 g for 5
min. After the addition of protease inhibitors and an energy regeneration
cocktail (energy mix) (Murray and Kirschner, 1989), extracts were either
used immediately or snap-frozen in liquid nitrogen and stored at  80 C.
Immunoprecipitation of myc6-Tcf3
Both cells of 2-cell embryos were injected with myc6-Tcf3 RNA (500 pg/
blastomere) and homogenized at stage 7.5 by resuspending the embryos
three times with a clipped P-200 pipet tip (cut so that the opening was
slightly smaller than the diameter of an embryo). The lysate (100  l) was
incubated with 25  l of anti-myc antibody-coupled beads (Santa Cruz Bio-
technology, Inc.) or control beads for 2 h at 4 C. Beads were washed and
the samples eluted (see Binding assay). The eluted samples were subjected
to SDS-PAGE followed by Western blotting using an anti-myc antibody
(9E10; Santa Cruz Biotechnology, Inc.), an anti-GSK3  antibody (Trans-
duction Laboratory), and an anti-CK1  antibody (Transduction Laboratory).
Tcf fractionation
Egg and embryonic lysates were prepared as described above. Supernatants
were obtained by centrifuging the lysates for 2 h at 100,000 g at 4 C. Equiv-
alent volumes of lysate and supernatant were subjected to SDS-PAGE fol-
lowed by Western blotting using either an anti-myc antibody (9E10; Santa
Cruz Biotechnology, Inc.) or an anti-Tcf monoclonal antibody (Exalpha Bio-
logical). Nuclear and cytoplasmic extracts were prepared from cultured 293
cells as described previously (Heintz and Stillman, 1988) with modifica-992 The Journal of Cell Biology | Volume 154, 2001
tions. Cells were washed in a cold hypotonic buffer (lysis buffer; 25 mM
Hepes, pH 7.7, 5 mM CH3COOK, 0.5 mM MgCl2, 1 mM DTT, 10  g/ml leu-
peptin, 10  g/ml aprotinin, 10  g/ml pepstatin, and 100  M PMSF) and
disrupted with 25 strokes in a dounce homogenizer. Nuclei were pelleted
at 4,000 rpm for 5 min in an Eppendorf centrifuge. The supernatant was re-
moved, recentrifuged at 4,000 rpm for 5 min, and transferred to a new tube.
The nuclear pellet was washed twice with PBS and resuspended in lysis
buffer with a volume equivalent to the supernatant fraction. SDS-PAGE and
Western blotting was performed on the nuclear and cytoplasmic fractions
using an anti–topoisomerase II monoclonal antibody (StressGen Biotechnol-
ogies) and an anti-Tcf monoclonal antibody (Exalpha Biological).
mRNA synthesis, translation in extracts, and degradation assays
Capped mRNAs were synthesized in vitro from linearized plasmid DNA
templates, purified using RNAeasy spin columns (QIAGEN), and resus-
pended in water to 0.2–0.5 mg/ml. For experiments requiring translations,
fresh extracts prepared as described above were supplemented with pla-
cental ribonuclease inhibitor (Promega) (1:100 ratio), mixed with mRNA to
a final concentration of 50–100 ng/ L, and incubated for 1–2 h at room
temperature. Translations were terminated by the addition of cyclohexim-
ide (100  g/mL) and were either used immediately in degradation assays
or snap-frozen in liquid nitrogen and stored at  80 C.
Degradation assays
For degradation assays, 6–8  L of Xenopus egg extracts were supple-
mented with 0.1  L cycloheximide (10 mg/mL), 0.2  L energy mix, 0.2  L
purified bovine ubiquitin (14 mg/mL), and 0.1–0.3  L [
35S]methionine-
labeled  -catenin. The reactions were incubated at room temperature for
3 h, and 1- L aliquots were removed at 0, 1, and 3 h for analysis by SDS-
PAGE and autoradiography.
Plasmids and recombinant proteins
Xenopus Tcf3,  NTcf3 (Molenaar et al., 1996), dsh, and  -catenin were sub-
cloned by PCR in the pCS2  vector.  -catenin deletion mutants were con-
structed by PCR in pCS2  and verified by in vitro translation of a protein of
the appropriate size. Xenopus GBP and CK1  were cloned from a stage 14
Xenopus plasmid library. MBP-GBP, MBP-cat449/645 (amino acids 449–
645 of Xenopus  -catenin), and MBP-CKI  were expressed in bacteria. His-
tagged Xenopus Tcf3 (his6-Tcf3), his6- N Tcf3 (lacking amino acids 1–31 of
Xenopus Tcf3), his6-APCm3 (amino acids 1342–2075 of Xenopus APC), and
his6-GSK3 were produced in baculovirus-infected Sf9 cells.
Kinase reactions
Kinase reactions were performed for 30 min at room temperature in kinase
buffer (20 mM Hepes, pH 7.5, 300 mM NaCl, 10 mM MgCl2, 2 mM DTT,
0.2% Tween-20, 50  M ATP, and 0.25  Ci/ L [ -
32P]ATP). For the phos-
phorylation of Tcf3 beads by CK1  and GSK3, Tcf3 beads (5  l) were incu-
bated with 1  M GSK3 or MBP-CK1  in a 50- l reaction containing 20
mM Hepes, pH 7.5, 300 mM NaCl, 10 mM MgCl2, 2 mM DTT, 0.2%
Tween-20, and 2 mM ATP. Reactions were performed for 1 h at room tem-
perature with rotation. Beads were subsequently washed with 3  1 ml of
binding buffer (see below) before addition of  -catenin.
Binding assays
Binding reactions using MBP fusion proteins were performed with the fu-
sion proteins bound to amylose beads (New England Biolabs, Inc.). Other
proteins were immobilized by cross-linking to Ultralink beads (Pierce
Chemical Co.). For binding experiments performed in extracts, Xenopus
egg extracts were diluted 1:5 in buffer containing 20 mM Hepes, pH 7.5,
300 mM NaCl, 1% Tween-20, 1 mg/mL BSA, and protease inhibitors.
Binding to purified or in vitro–translated proteins ([
35S]methionine-labeled
using the Promega TNT kit) was performed in the same buffer (2 h at 4 C).
After incubation, beads were washed with 3 mL of buffer A (20 mM Hepes,
pH 7.5, 300 mM NaCl, 1% Tween-20), 3 mL of buffer B (20 mM Hepes,
pH 7.5, 400 mM NaCl, 1% Tween-20), and 3 mL of buffer C (20 mM
Hepes, pH 7.5, 50 mM NaCl, 1% Tween-20). Bound proteins were eluted
with hot sample buffer and analyzed by SDS-PAGE followed by either au-
toradiography or Western blotting. Western analysis of GSK3 was per-
formed using a monoclonal antibody obtained from Transductions Labora-
tories. NH2-terminal Tcf4 peptide was obtained from Zymed Laboratories.
 -catenin–luciferase assays
10 ng of recombinant  -catenin–luciferase protein (1 mg/ml in 20 mM
Hepes, pH 7.4, and 50 mM NaCl) purified from baculovirus-infected Sf9
cells was injected into 2-cell stage Xenopus embryos and processed as de-
scribed previously (Salic et al., 2000).
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